Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.
Metoprolol is a relatively beta 1-selective beta-blocker used extensively to treat hypertension and angina and as a prophylaxis after myocardial infarction. Conventional formulations are usually administered twice daily and the drug has a tendency to lose its selectivity of action at higher plasma concentrations. Two controlled release formulations, metoprolol CR and metoprolol 'Oros', have made it possible to achieve sustained beta 1-blockade over an entire 24h period and to minimise the loss of selectivity associated with higher plasma concentrations. The CR formulation has been extensively investigated and is the major subject of this review. The 'Oros' formulation is pharmaceutically different from the CR, yet both produce similar plasma concentration profiles and comparable beta 1-blocking effects. The availability of these preparations occurs at a time when increasingly persuasive data are becoming available on the cardioprotective or coronary preventive action of metoprolol.
Kendall
M J
MJ
Department of Medicine, Queen Elizabeth Hospital, Birmingham, England.
Maxwell
S R
SR
Sandberg
A
A
Westergren
G
G
D001682:Biological Availability; D003692:Delayed-Action Preparations; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008790:Metoprolol / Q000493:pharmacokinetics* / Q000494:pharmacology
D003692:Delayed-Action Preparations; D008790:Metoprolol